News

The Comfort Phase III Psoriasis study, is designed to evaluate the efficacy and safety of daily Piclidenoson, administered orally compared to Apremilast (Otezla) and placebo, in 407 patients

The partnership will assess Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy in a phase 2 study in patients with metastatic triple negative breast cancer (TNBC). The trial has been

The agreement marks a first for CCAB as part of its new business strategy, which aims to attract investment to create successful life sciences companies in Canada. The

As per the research published in Nature Communications, the scientists at the University of Cambridge discovered that a protein called BCL11A is found in high amounts in lung

The global partnership, which will exclude the Greater China region, is expected to fetch more than $350m to Kelun-Biotech in addition to royalties based on annual net sales.

The randomized, double-blind, placebo-controlled Phase 2 study will be conducted across 50 sites in Europe, the U.S., Canada, Israel, and Turkey, and enroll approximately 260 patients. The Company

AC Immune CEO Prof Andrea Pfeifer said: “We are delighted with the progress of ACI-24, the anti-Abeta vaccine, derived from our proprietary SupraAntigenTM platform. In addition to the

The approval follows the priority review of Alecensa in China, just eight and nine months after European Medicines Agency (EMA) and US Food and Drug Administration (FDA) approvals,

Approval for this indication has been granted under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be